Eton Pharmaceuticals, INC Form 4 insider transactions

Eton Pharmaceuticals' CFO, James R. Gruber, sold 41,713 shares of common stock over two days in August 2025, pursuant to a Rule 10b5-1 plan.

David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc. (ETON), reported the sale of 34,000 shares of common stock through a Rule 10b5-1 trading plan in mid-June 2025.

Opaleye Management Inc., a significant 10% owner of Eton Pharmaceuticals, Inc. (ETON), has increased its beneficial ownership by purchasing 7,930 shares of common stock for approximately $125,490.

Sean Brynjelsen, President and CEO and a 10% owner of Eton Pharmaceuticals, Inc., reported the sale of 210,000 shares of common stock over three trading days in early June 2025.

Jennifer McKie Adams, a director at Eton Pharmaceuticals, was granted stock options for 25,000 shares on January 3, 2025.

Director Norbert G. Riedel exercised employee stock options to acquire common stock in Eton Pharmaceuticals on January 3, 2025.

Director Charles J Casamento of Eton Pharmaceuticals acquired 25,000 employee stock options on January 3, 2025.

Director Norbert Riedel received options to purchase 25,000 shares of Eton Pharmaceuticals stock, vesting quarterly over 12 months.

Eton Pharmaceuticals director Paul V. Maier was granted 25,000 employee stock options on January 3, 2025.

Eton Pharmaceuticals' CEO, Sean Brynjelsen, acquired stock options and restricted stock units on January 3, 2025, as reported in a Form 4 filing with the SEC.

David Krempa, Chief Business Officer of Eton Pharmaceuticals, reports acquisition of stock options and restricted stock units.

James R. Gruber, CFO of Eton Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Opaleye Management Inc. reports purchasing 10,000 shares of Eton Pharmaceuticals at an average price of $7.9814 on October 23, 2024, increasing its indirect holdings.

Opaleye Management Inc., a significant shareholder of Eton Pharmaceuticals, Inc., has increased its holdings through a series of open market purchases in early October 2024.

David Krempa, Chief Business Officer of Eton Pharmaceuticals, received 42,088 restricted stock units on October 2, 2024, vesting annually over four years.

Opaleye Management Inc. reports acquiring additional shares of Eton Pharmaceuticals through direct purchases for both Opaleye, L.P. and a managed account.